Boehringer Ingelheim and Elixiron’s EI-001 Achieves Successful Clinical Submission

Shanghai, China, August 23, 2021 – Boehringer Ingelheim today announced that EI-001, a monoclonal antibody co-developed with Elixiron Immunotherapeutics, has successfully completed clinical submission and is set to begin a Phase I clinical trial in Australia. EI-001 is a fully human antibody generated through single B-cell technology, targeting a pathway closely associated with the pathology of diseases such as vitiligo and hepatitis B. The clinical application of this antibody is expected to bring significant benefits to patients affected by these conditions. More details to follow.